Omeprazol Aurovitas Pharma (Omeprazole)

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining.
• Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition.
• Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication success when used with antibiotics.
• NSA‑ID‑induced gastropathy: reduces risk of ulcer formation in patients requiring chronic NSAID therapy.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells, inhibiting the final step of acid secretion. By blocking this pump, it markedly lowers gastric acidity, allowing mucosal healing and symptom control in acid‑related disorders.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea: occasional and transient.
• Abdominal pain or discomfort.
• Flatulence: mild bloating.
• Constipation: infrequent.

Serious or Rare Side Effects

• Severe allergic reactions (anaphylaxis, angioedema).
• Clostridioides difficile‑associated colitis.
• Acute interstitial nephritis.
• Low magnesium levels (hypomagnesemia) with long‑term use.
• Bone fractures (hip, wrist, spine) associated with prolonged therapy.
• Liver enzyme elevations (hepatitis).

When prescribing Omeprazol Aurovitas Pharma, clinicians should consider several safety aspects:

• Assess renal and hepatic function: dose adjustment may be needed in severe impairment.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor long‑term users: watch for magnesium deficiency and bone health.
• Use the lowest effective dose: limit duration to the shortest period required.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Store at ambient temperature: keep in the original pack, protect from moisture.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atorvastatin: increased plasma concentrations, higher risk of myopathy.
• Warfarin: potential increase in INR, requiring closer monitoring.

Moderate Interactions (Monitor Closely)

• Digoxin: elevated levels may occur, monitor serum concentrations.
• Methotrexate: reduced renal clearance, watch for toxicity.
• Ketoconazole and itraconazole: decreased absorption, may need dose adjustment.
• Phenytoin: altered metabolism, monitor therapeutic levels.